Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events

http://academiccme.com/wp-content/uploads/2018/06/iStock-530199842-wpcf_400x400.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credits™
Activity Dates: June 1, 2018 - May 31, 2019

 

Program Overview

This CME activity will review optimal treatment strategies and recent clinical trial data for patients with dyslipidemia, as presented at the American College of Cardiology 2018 in Orlando, Florida. Four expert faculty, led by Dr. Christopher Cannon, will analyze the science of LDL cholesterol and how it relates to cardiovascular events. Recent clinical trial data for PCSK9 inhibitors, including data on the prevention of heart attack and stroke will be reviewed. The faculty will relay best practices on how to collaborate with the healthcare team to apply PCSK9 inhibitors into clinical strategies for the treatment of dyslipidemia and prevention of cardiovascular events. Upon completing this activity, learners will gain better insight on the treatment of dyslipidemia patients.

Target Audience

This activity has been designed to meet the educational needs of cardiologists, primary care physicians, internists, and other healthcare providers involved in the management of patients with dyslipidemia and cardiovascular disease

Learning Objectives

1. Review the science of LDL cholesterol and the relationship to cardiovascular events

2. Analyze recent clinical trial data for PCSK9 Inhibitors, including data on the prevention of heart attack and stroke

3. Collaborate with the healthcare team to apply PCSK9 inhibitors into clinical strategies for the treatment of dyslipidemia and prevention of cardiovascular events

Faculty

Cannon Headshot copyChristopher P. Cannon, MD
Professor of Medicine, Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

Prof106Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
 
—-
erin-bohula-mayErin A. Bohula May, MD, DPhil
Cardiovascular Medicine and Critical Care Specialist
Brigham and Women’s Hospital
Instructor in Medicine
Harvard Medical School
Boston, MA
—-
Giugliano Headshot copyRobert P. Giugliano, MD, SM
Physician, CV Medicine
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
— 
 —-

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Christopher P. Cannon, MD Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amgen Inc.; Amarin Corporation; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; GlaxoSmithKline Plc; Kowa; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.Grant/Research Support: Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Deepak L. Bhatt, MD, MPH Grant/Research Support: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, The Medicines Company
Erin A. Bohula May, MD, DPhil Consultant/Advisor: Merk, Daiichi Sankyo, Servier, Lexicon, NovartisGrant/Research Support: Merk, Eisai, Astra Zeneca, Amgen
Robert P. Giugliano, MD, SM Consultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company Limited; GlaxoSmithKline Plc; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.Grant/Research Support: Amgen Inc.Speaker’s Bureau: Amgen Inc.; Daiichi Sankyo Company Limited; Merck & Co., Inc.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by:

68151cf1-f976-429e-b78e-bc0618e6d2a5